EnBiotix

EnBiotix is a biotechnology company leveraging engineered bacteriophages, antimicrobial peptides, and synthetic biology to develop novel anti-infectives and revitalize existing antibiotics, aiming to address the global rise of drug-resistant bacterial infections. The company has a pipeline including engineered phage candidates for both animal and human health, as well as programs targeting bacterial infections, cystic fibrosis, lung diseases, and oncology. Their collaboration with Mayo Clinic on an engineered phage candidate for Staphylococcus infections in prosthetic joints was advancing toward clinical trials as of 2018–2019, and they have partnered with Elanco for animal health applications. No publicly available information indicates late-stage trials or commercial products at this time[1][2][4].